News

Vifor Pharma has announced the acquisition of Sanifit Therapeutics, a Spanish clinical-stage cardio-renal biopharmaceutical company focused on treatments for end-stage kidney disease…
Read More...

REGENXBIO Inc. announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for RGX-202, a potential one-time gene therapy for the treatment of Duchenne…
Read More...

Arrowhead Pharmaceuticals Inc. announced that it entered into an exclusive license agreement with GlaxoSmithKline under which GSK will develop and commercialize ARO-HSD, Arrowhead’s…
Read More...

Xencor, Inc. a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, and Zenas…
Read More...

CStone Pharmaceuticals, a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and precision medicines,…
Read More...

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that Gilead has exercised its options to three programs in Arcus’s clinical-stage portfolio, including both anti-TIGIT…
Read More...

Novo Nordisk announced that it has entered into a definitive agreement to acquire Dicerna Pharmaceuticals (Dicerna). The acquisition of Dicerna’s ribonucleic acid interference (RNAi)…
Read More...

EQRx, a new type of pharmaceutical company committed to developing and delivering important new medicines to patients at radically lower prices, and Evotec SE, a leading life science…
Read More...

Pfizer Inc. announced the successful completion of its acquisition of Trillium Therapeutics, a clinical stage immuno-oncology company developing innovative therapies for the treatment…
Read More...

GlaxoSmithKline plc and Vir Biotechnology, Inc. announced US government contracts totalling approximately $1 billion (USD) to purchase sotrovimab, an investigational monoclonal antibody…
Read More...

Pfizer Inc. announced an agreement with the U.S. government to supply 10 million treatment courses of its investigational COVID-19 oral antiviral candidate, PAXLOVID™ (PF-07321332;…
Read More...

Novavax, Inc. a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII),…
Read More...

BioAgilytix, a leading global contract research organization (CRO), announced an agreement to be further capitalized by Cinven, a leading international private investment firm focused…
Read More...

Alcami, a leading United States-based contract development and manufacturing organization (CDMO), announced that they have signed a master laboratory services agreement with Novavax, a…
Read More...

ACELYRIN, INC., an innovative clinical-stage biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies, today…
Read More...

Lonza announced it has invested in additional microbial development capabilities in Switzerland. The investment will support increased capacity of development services targeting…
Read More...

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced an exclusive, target-specific license and option agreement with LegoChem Biosciences Inc. a…
Read More...

Kala Pharmaceuticals, Inc. a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye,…
Read More...

Arranta Bio, a leading contract development and manufacturing organization (CDMO) supporting advanced therapy pioneers, announced the completion of the sale of its process development…
Read More...

Moderna Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, confirmed that Health Canada authorized the use of a booster dose of the Moderna…
Read More...